"As AMRI celebrates its 25th anniversary, CPhI presents the perfect opportunity to reveal AMRI and Euticals as one combined company that can offer a greatly expanded portfolio of market-leading APIs and world-class capabilities in niche and high-barrier-to-entry technologies," said Margalit Fine, executive vice president of API at AMRI. "In addition to an extensive API portfolio, we can now offer our customers U.S. and European-based chemical development expertise for early stage compounds, custom synthesis and contract manufacturing expertise, as well as extensive technology expertise in specialty areas such as hydrogenation, fermentation, photocatalytic chemistry, bio transformation, industrial chromatography, flow chemistry and spray drying."
Attracting about 2,490 exhibitors and in excess of 36,000 participants from more than 150 countries, CPhI Worldwide is one of the largest events in the pharma industry. This year, CPhI will take place in Barcelona and run between October 4th and 6th. Visit AMRI at booth numbers 4F46 or 3Q10.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product Manufacturing (DPM), and Fine Chemicals. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-to-unveil-powerful-portfolio-of-apis-and-capabilities-at-cphi-in-barcelona-300337900.html